TGFB1 and atrial fibrillation: The lower-dose spironolactone was superior to the higher-dose spironolactone in reducing atrial fibrosis and the expression of TGF-β1, shortening the P-wave duration and the PR interval, and reducing the incidence as well as the duration of AF.